F-star Therapeutics is a biotechnology company focused on developing next-generation immunotherapies to transform the lives of cancer patients. The company operates in the biopharmaceutical market and primarily serves patients with various types of cancer. F-star's core business revolves around its proprietary bispecific antibody technology, which aims to enhance the immune system's ability to detect and destroy cancer cells. The company generates revenue through the development and commercialization of its drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies. F-star's wholly-owned pipeline includes several first and best-in-class drug candidates designed to prevent tumors from evading the body's defense mechanisms. The business model is centered on advancing these drug candidates through clinical trials and eventually bringing them to market, either independently or through strategic partnerships. The company's mission is to keep its approach patient-focused, simple, and driven by science.

Keywords: biotechnology, immunotherapy, cancer, bispecific antibodies, drug development, clinical trials, biopharmaceutical, tumor defense, patient-focused, partnerships.